Novus therapeutics, inc. (NVUS)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Sep'13
Revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

0

Operating expenses
Research and development

6,787

8,128

9,535

9,677

8,709

6,817

4,570

3,436

2,640

2,022

-4,856

-4,320

-4,261

3,191

17,309

24,747

30,010

32,638

28,709

23,043

21,580

14,577

13,477

0

0

0

General and administrative

5,900

6,056

6,926

7,363

7,431

7,243

7,018

7,618

11,891

11,099

6,971

5,087

-706

1,937

7,792

10,644

13,431

12,623

11,741

11,924

10,290

8,885

7,089

0

0

0

Total operating expenses

14,554

16,051

16,461

17,040

16,140

14,060

11,588

11,054

14,531

13,121

2,115

767

-4,967

5,128

25,101

35,391

43,441

45,261

40,450

34,967

31,870

23,462

20,566

0

0

0

Loss from operations

-14,554

-16,051

-16,461

-17,040

-16,140

-14,060

-11,588

-11,054

-14,531

-13,121

-2,115

-767

4,967

-5,128

-25,101

-35,391

-43,441

-45,261

-40,450

-34,967

-31,870

-23,462

-20,566

0

0

0

Interest income and other income, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

0

-

-

-

0

0

-

Interest income and other income (expense), net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

Interest and other income (expense), net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

Other income (expense), net

76

40

20

-4

0

-5

-13

-21

-17

5

0

0

0

-

0

0

-

-

-

-

-

-

-

-

-

-

Warrant inducement expense

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss and comprehensive loss

-19,307

-16,011

-16,441

-17,044

-16,140

-14,065

-11,601

-11,075

-14,548

-13,116

-2,198

-1,263

4,397

-5,655

-25,480

-35,298

-43,253

-45,087

-40,278

-34,815

-31,709

-23,296

-20,453

0

0

0

Net loss attributable to common stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Net loss per share, basic and diluted

-0.47

-0.27

-0.22

-0.35

-0.52

-0.49

-0.37

-0.34

-0.36

0.04

-0.43

-1.32

-0.59

4.65

-4.35

-2.25

-0.51

-0.49

-0.53

-0.40

-0.59

20.58

-2.71

-11.68

-9.79

-6.82

Weighted-average common shares outstanding, basic and diluted

17,267

13,044

12,974

11,751

9,427

9,445

9,420

9,407

7,749

7,198

6,943

4,154

413

-21,253

81

77

22,625

22,590

22,540

22,421

22,384

22,523

2,357

501

495

493

Net loss

-19,307

-16,011

-16,441

-17,044

-16,140

-14,065

-11,601

-11,075

-14,548

-13,116

-2,198

-1,263

4,397

-5,655

-25,480

-35,298

-43,253

-45,087

-40,278

-34,815

-31,709

-23,296

-20,453

0

0

0

Unrealized gains on marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

0

-

-

-

-

-

-

Total other comprehensive income

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

0

-

-

-

-

-

-

Total comprehensive loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-43,258

-45,142

-40,452

-34,460

0

-

0

0

-

-